NgoFebhuwari 2023, i-Food and Drug Administration (FDA) yasheshisa ukugunyazwa kwe-tucatinib (Tukysa, Seagen Inc.) kanye ne-trastuzumab yokwelashwa kwe-RAS wild-type HER2-positive colorectal cancer osusabalele noma ongakwazi ukuphinda ulashwe.